

## Open Pharma position statement on open access

Pharmaceutical companies, which fund approximately half of all biomedical research,<sup>1</sup> are now leaders in the publication and disclosure of research.<sup>2,3</sup> However, access to much company-funded research is restricted by journal paywalls.<sup>4</sup> We, as Open Pharma, a group of pharmaceutical companies and other research funders, alongside healthcare professionals, regulators, patients, publishers and other stakeholders in healthcare, recognize the importance of publishing research with open access, where papers can be read without payment of a one-off access charge or subscription. Open access ensures that the highest quality, peer-reviewed evidence is available to anyone who needs it, anywhere in the world. Publishing with open access improves transparency, advances medical science and, we believe, ultimately improves patient care.

### Our immediate priority

Our immediate priority is to secure authors publishing company-funded research the same right to publish open access as authors publishing research funded by other sources, so that all research can be made free to read from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in requiring all the research they fund to be published with open access, without impacting on journal choice.<sup>5-7</sup> In order to provide publishers the time to adapt their policies and protect their copyright interests, any variant of Creative Commons or equivalent licence could be used.

### Our long-term goal

Our long-term goal is to secure authors publishing company-funded research the same terms as authors publishing research funded by other sources, so that all research can be made free to read – and reuse – from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in maximizing the impact of the research they fund on patient health. Open Pharma is committed to working closely with publishers and pharmaceutical companies to ensure that the gold standard Creative Commons Attribution (CC BY) licence can sustainably be used.<sup>8</sup>

### Acknowledgements

This Open Pharma position statement on open access represents the opinions of the individual members: Catherine Skobe (Pfizer), Chris Rains (Takeda), Chris Winchester (Oxford PharmaGenesis), Julie Newman (Gilead), Lise Baltzer (Novo Nordisk), Sarah Sabir (Oxford PharmaGenesis) and Valerie Philippon (Takeda), and not necessarily those of their individual companies. We thank the members, supporters and followers of Open Pharma for their input and valuable discussion.

## References

1. Dorsey ER, de Roulet J, Thompson JP *et al.* [Funding of US biomedical research, 2003–2008](#). *JAMA* 2010;303:137–43.
2. Baronikova S, Purvis J, Southam E *et al.* [Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment](#). *BMJ Evidence-Based Medicine* 2019;bmjebm–2018–111145.
3. Warren M. Big pharma is embracing open-access publishing like never before. *Nature*, 2019. Available from: <https://www.nature.com/articles/d41586-019-00610-2> (Accessed 3 October 2019).
4. Ellison TS, Koder T, Schmidt L, Williams A, Winchester CC. [Open access policies of leading medical journals: a cross-sectional study](#). *BMJ Open* 2019;9:e028655.
5. Collins E. [Publishing priorities of biomedical research funders](#). *BMJ Open* 2013;3:e004171.
6. Baronikova S, Desai SY, Philippon V, Rains CP. [An assessment of open access publishing at Shire before and after implementation of the open access publication policy](#). *Curr Med Res Opin* 2019;35(Suppl 2):31.
7. Lang H, Winchester CC, Gattrell W. [Open access publishing of research affiliated to Ipsen, 2013–2017: a baseline assessment](#). *Curr Med Res Opin* 2019;35(Suppl 2):39.
8. Tennant JP, Waldner F, Jacques DC *et al.* [The academic, economic and societal impacts of Open Access: an evidence-based review](#). *F1000Res* 2016;5:632.

## Endorsements

### Publishers

Betasciencepress Publishing

*E*cancer

F1000 Research Ltd.

Frontiers Media SA

Future Science Group

MDPI

PLOS

Wiley

### Organizations

Ataxia & Me

Autoinflammatory UK

Cambridge Rare Disease Network

Canadian Organization for Rare Disorders

Centro Español de Investigación Farmacoepidemiológica (CEIFE)

Cinclus Pharma Holding AB

DSL Consulting, LLC

Epi-Fit

Galapágos NV

Inspiring STEM

International Kidney Cancer Coalition

Ipsen

KAN Consulting MON. I.K.E

Kidney Research UK

M-CM Network

Observational and Pragmatic Research Institute Pte

Outcomes Positive, Inc

Oxford Health Policy Forum

Oxford PharmaGenesis

Pedalling4ACure

SCN2A Australia

Scott Pharma Solutions

Scriva Medical Communications

Sequoia Medical Communications Ltd

Solanum Medical Communications Ltd

SUDEP Action

The Aarskog Foundation

<https://doi.org/10.6084/m9.figshare.10003304>

ThinkSCIENCE, Inc.  
Zimbabwe Evidence Informed Policy Network

### Individuals

Mary Kunjappu, Alexion Pharmaceuticals  
Kenneth Pomerantz, Alexion Pharmaceuticals  
Börje Wernersson, formerly of AstraZeneca  
Saga Johansson, formerly of AstraZeneca  
Alan Thomas, Ataxia & Me  
Scott Armit, Ataxia & Me  
John Wallace, Autoinflammatory UK  
Gavin Giovannoni, Barts and the London School of Medicine and Dentistry  
Roland J.W. Meesters, Betasciencepress Publishing  
E. Andrew Balas, Biomedical Research Innovation Laboratory, Augusta University  
Durhane Wong-Rieger, Canadian Organization for Rare Disorders  
Luis Alberto García Rodríguez, Centro Español de Investigación Farmacoepidemiológica (CEIFE)  
Peter Unge, Cinclus Pharma Holding AB  
Val Tate, Communications Consultant  
Raj Kadadai, Cure SCA3  
Inmaculada Silos-Santiago, Decibel Therapeutics  
Douglas Levine, DSL Consulting  
Brian S. Alper, EBSCO Information Services  
Katie Foxall, ecancer  
Laure Lacoïn, Epi-Fit  
Wilbur Liu, Haalthy  
Laverne Mooney, Independent Consultant  
Linda Edmonson, Innovative Strategic Communications  
Tim Day, Innovative Strategic Communications  
Martin Delahunty, Inspiring STEM  
Anna Baikova, Ipsen  
Kamila Novak, KAN Consulting MON. I.K.E  
Christy Collins, M-CM Network  
Grigorios Leontiadis, McMaster University  
Franck Vazquez, MDPI  
Rita Moreira de Silva, Medscape  
Alben Sigamani, Narayana Health  
Michael De Rosa, National Ataxia Foundation  
Peter Llewellyn, NetworkPharma Ltd.  
Pali Hungin, Newcastle University  
Klaus Boberg, Novo Nordisk

<https://doi.org/10.6084/m9.figshare.10003304>

Heather Piwowar, Our Research  
Tracy Bunting, Outcomes Positive, Inc  
Serena Vanzan, Oxford Brookes University  
Kajsa Wilhelmsson, Oxford Health System Reform Group  
Adele Buss, Oxford PharmaGenesis  
Adeline Rosenberg, PharmaGenesis  
Alison Hillman, Oxford PharmaGenesis  
Anja Becher, Oxford PharmaGenesis  
Bobby Thompson, Oxford PharmaGenesis  
Cassidy Fiford, Oxford PharmaGenesis  
Emma Bolton, Oxford PharmaGenesis  
Francesca Ounsworth, Oxford PharmaGenesis  
Jessica Hardy, Oxford PharmaGenesis  
Julie Beeso, Oxford Pharmagenesis  
Mark Rolfe, Oxford PharmaGenesis  
Michael Molloy-Bland, Oxford PharmaGenesis  
Nicolas Bertheleme, Oxford PharmaGenesis  
Paul Farrow, Oxford PharmaGenesis  
Richard White, Oxford PharmaGenesis  
Sally Bardell, Oxford PharmaGenesis  
Sarah Sabir, Oxford PharmaGenesis  
Steph Macdonald, Oxford PharmaGenesis  
Tamzin Gristwood, Oxford PharmaGenesis  
Tim Ellison, Oxford PharmaGenesis  
Tim Koder, Oxford PharmaGenesis  
Trevor Sills, Oxford PharmaGenesis  
Zoe Watts, Oxford PharmaGenesis  
Graham Shelton, Oxford University Hospitals Foundation  
Charles Boyce, patient  
Emily Medina, patient  
Jeannie Smithball, patient  
Danielle Grover, patient advocate  
Elizabeth Kinder, patient advocate  
Richard Stephens, patient advocate  
Tracy Zervakis, patient advocate  
Trishna Bharadia, patient advocate  
Rosario Strano, Pedalling4Cure  
Angela Sykes, Pfizer  
Courtney Leo, Pfizer  
J.R. Meloro, Pfizer

<https://doi.org/10.6084/m9.figshare.10003304>

Nervana Habashy, Pfizer  
Ellie Challis, PTEN UK & Ireland  
Dermot Ryan, Respiratory Effectiveness Group  
Kris Pierce, SCN2A Australia  
Susan Scott, Scott Pharma Solutions  
Evguenia Alechine, Science Communicator  
Jim Gavin, Scriva Medical Communications  
David Peters, Sequoia Medical Communications Ltd  
Sophie Berry, Smith & Nephew  
John Gonzalez, Solanum Medical Communications Ltd.  
Amy Whereat, Speak the Speech Consulting  
Laura Paglione, Spherical Cow Group  
Jane Hanna, SUDEP  
William Spalding, Takeda  
Raquel Billiones, Takeda Vaccines  
Victoria Woods, Patient and Public Engagement, Thames Valley Cancer Alliance at NHS England  
Zbys Fedorowicz, The Care Combine and North West Anglia NHS Foundation Trust  
Stuart Taylor, The Royal Society  
Caryn Jones, THINK Science  
John Pernick, THINK Science  
Erik Michels, UCB  
Rachel Giles, Regenerative Medicine Center, UMC Utrecht  
Meredith Hays, Department of Medicine, Uniformed Services University  
Emmanuel Picavet, Université Paris 1 Panthéon-Sorbonne  
Martin Rossor, University College London  
Stephen Bradley, University of Leeds  
Robert Sim, Department of Respiratory Science, University of Leicester  
Iain Chalmers, Centre for Evidence-Based Medicine, University of Oxford  
Edith Sim, Department of Pharmacology, University of Oxford  
Chas Bountra, Nuffield Department of Clinical Medicine, University of Oxford  
Stevan Harnad, University of Southampton  
Álvaro Díaz, Departamento de Biociencias, Universidad de la República, Uruguay  
Ronald Munatsi, Zimbabwe Evidence Informed Policy Network

*Endorsements last updated on 04 June 2020*